JP2018522046A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522046A5
JP2018522046A5 JP2018505695A JP2018505695A JP2018522046A5 JP 2018522046 A5 JP2018522046 A5 JP 2018522046A5 JP 2018505695 A JP2018505695 A JP 2018505695A JP 2018505695 A JP2018505695 A JP 2018505695A JP 2018522046 A5 JP2018522046 A5 JP 2018522046A5
Authority
JP
Japan
Prior art keywords
chloro
substituted
phenyl
triazol
oxopyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018505695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522046A (ja
JP6785838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045276 external-priority patent/WO2017023992A1/en
Publication of JP2018522046A publication Critical patent/JP2018522046A/ja
Publication of JP2018522046A5 publication Critical patent/JP2018522046A5/ja
Application granted granted Critical
Publication of JP6785838B2 publication Critical patent/JP6785838B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018505695A 2015-08-05 2016-08-03 新規な置換グリシン誘導のfxia阻害剤 Active JP6785838B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201267P 2015-08-05 2015-08-05
US62/201,267 2015-08-05
PCT/US2016/045276 WO2017023992A1 (en) 2015-08-05 2016-08-03 Novel substituted glycine derived fxia inhibitors

Publications (3)

Publication Number Publication Date
JP2018522046A JP2018522046A (ja) 2018-08-09
JP2018522046A5 true JP2018522046A5 (enExample) 2019-09-12
JP6785838B2 JP6785838B2 (ja) 2020-11-18

Family

ID=56618292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505695A Active JP6785838B2 (ja) 2015-08-05 2016-08-03 新規な置換グリシン誘導のfxia阻害剤

Country Status (7)

Country Link
US (2) US10336730B2 (enExample)
EP (1) EP3331872B1 (enExample)
JP (1) JP6785838B2 (enExample)
KR (1) KR102697816B1 (enExample)
CN (1) CN108137549B (enExample)
ES (1) ES2754599T3 (enExample)
WO (1) WO2017023992A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2762987T3 (es) 2015-06-19 2020-05-26 Bristol Myers Squibb Co Macrociclos de diamida como inhibidores del factor XIA
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3868753B1 (en) 2015-07-29 2022-12-21 Bristol-Myers Squibb Company Factor xia macrocyclic inhibitors bearing a non-aromatic p2' group
CN107849026B (zh) 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
WO2017023992A1 (en) 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors
JP7112715B2 (ja) * 2018-03-23 2022-08-04 株式会社Kyulux 有機発光素子材料合成用原料および化合物
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
TW202019904A (zh) * 2018-07-19 2020-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種凝血因子XIa抑制劑及其中間體的製備方法
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
CN112047931B (zh) * 2019-06-06 2024-03-08 上海美悦生物科技发展有限公司 FXIa凝血因子抑制剂、其药物组合物和用途
CN112341377B (zh) * 2019-08-09 2024-05-14 上海美悦生物科技发展有限公司 一种杂环类化合物及其应用
KR20220084301A (ko) * 2019-09-27 2022-06-21 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 FXIa 억제제와 이의 제조 방법 및 의약 용도
CN113005176A (zh) * 2019-12-20 2021-06-22 深圳市帝迈生物技术有限公司 稳定剂、凝血酶原时间检测试剂及其制备方法、试剂盒
ES3048448T3 (en) * 2020-07-22 2025-12-10 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
EP4215525A4 (en) * 2020-09-17 2024-08-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Piperazine derivative, preparation method therefor and use thereof
WO2022083706A1 (zh) * 2020-10-23 2022-04-28 深圳信立泰药业股份有限公司 FXIa抑制剂化合物的盐及其制备方法和医药用途
CN115427043B (zh) * 2020-10-23 2023-04-07 深圳信立泰药业股份有限公司 FXIa抑制剂化合物或其盐的医药用途
CN112679446A (zh) * 2020-10-26 2021-04-20 都创(上海)医药科技有限公司 一种合成反式-3-(3-氯-2-氟-6-(1h-四氮唑-1-基)苯基)丙烯酸的方法
WO2022122035A1 (zh) * 2020-12-11 2022-06-16 上海领泰生物医药科技有限公司 凝血因子XIa抑制剂及其制备方法和应用
CN112675173B (zh) * 2020-12-25 2022-04-05 华南理工大学 FXIa抑制剂化合物或其盐的医药用途
CN115461330A (zh) * 2021-03-18 2022-12-09 深圳信立泰药业股份有限公司 FXIa抑制剂化合物杂质及其制备方法和用途
CN116283750B (zh) * 2021-09-09 2025-02-07 成都泰和伟业生物科技有限公司 一种杂环酰胺类衍生物及其制备方法和用途
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
TW202515882A (zh) 2023-06-30 2025-04-16 大陸商深圳信立泰藥業股份有限公司 一種多取代的大環化合物及其製備方法與應用
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008086A (en) * 1972-04-15 1977-02-15 Konishiroku Photo Industry Co., Ltd. Silver halide emulsion containing photographic yellow coupler
US3900483A (en) * 1972-04-15 1975-08-19 Konishiroku Photo Ind ' -(2(1h)pyridone)+65 -pivalyl-5-(' -2,4-di-t-amyl-phenoxybutyramide)-acetanilides and derivatives
DE2960194D1 (en) 1978-05-08 1981-04-16 Ucb Sa Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
JPS57501328A (enExample) 1980-08-07 1982-07-29
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
EP1395560A1 (en) 2001-05-23 2004-03-10 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
BRPI0212726B8 (pt) 2001-09-21 2021-05-25 Bristol Myers Squibb Co compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos
US20060122184A1 (en) 2002-12-05 2006-06-08 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
AU2003292748A1 (en) 2002-12-24 2004-07-22 Daiichi Pharmaceutical Co., Ltd. Novel ethylenediamine derivatives
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
WO2005061462A2 (en) 2003-12-19 2005-07-07 Neurogen Corporation Diaryl pyrazole derivatives and their use as neurokinin-3 receptor modulators
WO2006090234A1 (en) 2005-02-22 2006-08-31 Ranbaxy Laboratories Limited Heterocyclic derivatives as cell adhesion inhibitors
WO2007081570A2 (en) 2005-12-30 2007-07-19 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
TW200829171A (en) 2006-11-17 2008-07-16 Nihon Nohyaku Co Ltd Haloalkyl sulfonanilide derivatives or salts thereof, herbicide using it as effective constituent and use-method thereof
ATE517873T1 (de) 2006-12-07 2011-08-15 Novartis Ag 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
EP2125750B1 (en) 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009078498A1 (en) 2007-12-17 2009-06-25 Green Cross Corporation Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
US8598160B2 (en) 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AR071069A1 (es) 2008-03-26 2010-05-26 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso para la prevencion o el tratamiento de cancer
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
CA2722811C (en) 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2410858B1 (en) 2009-03-23 2016-09-07 Merck Sharp & Dohme Corp. P2x3 receptor antagonists for treatment of pain
JP2010280638A (ja) 2009-06-08 2010-12-16 Nippon Nohyaku Co Ltd ハロアルキルスルホンアニリド誘導体又はその塩類及びこれを有効成分とする除草剤並びにその使用方法
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
ES2579832T3 (es) * 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
CN104136431B (zh) 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
HUE032622T2 (en) * 2012-08-03 2017-10-30 Bristol Myers Squibb Co Dihydropyridone p1 as factor xia inhibitors
ES2627281T3 (es) 2013-02-06 2017-07-27 Merck Patent Gmbh Derivados del ácido carboxílico sustituidos como agregados agrecanasa para el tratamiento de la artrosis
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2017023992A1 (en) 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors

Similar Documents

Publication Publication Date Title
JP2018522046A5 (enExample)
AU2016240033B2 (en) 1-cyano-pyrrolidine compounds as USP30 inhibitors
AU2022201352A1 (en) Pyrazole derivatives as MALT1 inhibitors
JP2019504821A5 (enExample)
AU2011240808B2 (en) 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
EP2566477B1 (en) Amino-quinolines as kinase inhibitors
CA2775475C (en) Pyridinylimidazolone derivatives for the inhibition of pi3 kinases
HUE032770T2 (en) Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
JP2014521711A5 (enExample)
EP2603218B1 (en) Quinolyl amines as kinase inhibitors
JP2019504821A (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2016500671A5 (enExample)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
US10023576B2 (en) Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
RU2013120966A (ru) ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
RU2017105296A (ru) Новые соединения
WO2015015318A4 (en) Novel quinazolinones as bromodomain inhibitors
CZ20031676A3 (en) Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors
PT2081937E (pt) Moduladores de proteína-cinase de triazolo-piridazina
ES2550201T3 (es) Moduladores de la PDE10
HRP20250272T1 (hr) Derivati benzimidazola i njihova uporaba
RU2014119244A (ru) Гетероциклические соединения и способы их использования
CA3202212A1 (en) Indole derivatives useful in treating conditions associated with cgas
CN114945571A (zh) 环状化合物及其使用方法